Article

Employee fringe benefits are often tax deductible

The most preferred benefit program may be the least expensive for yourpracticeThe difficulty in recent years of attracting and retaining employeeshas eased somewhat, largely because of the state of the economy. Many ofthe problems faced by urologists in finding and keeping good, qualifiedworkers remain, however, especially for many small, understaffed, or financiallytroubled practices.

Related Videos
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Sima Porten, MD, on gene-environment interactions in bladder cancer development
1 expert in this video
Resective Surgery and Minimally Invasive Procedures For BPH
Naeem Bhojani, MD, expands on key findings from WATER III trial
Naeem Bhojani, MD, expands on key findings from WATER III trial
Hailey Frye answers a question during a Zoom video interview
Hailey Frye discusses improvement of pain management for nephrolithiasis
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
1 expert is featured in this series.
Key Limitations of MAIC Analyses
1 expert is featured in this series.
Matching-Adjusted Indirect Comparisons in mHSPC
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
How rBCG EAP could open up access for Anktiva in bladder cancer
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Operationalizing TAR-200 and Other Delivery Systems in Practice
Operationalizing TAR-200 and Other Delivery Systems in Practice
Related Content
Study underway to assess 3-fraction SBRT regimen in prostate cancer
April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke
"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
“Go big or go small”: Current and emerging tools in kidney stone management
April 11th 2025

“Go big or go small”: Current and emerging tools in kidney stone management

Brian R. Stork, MD Hannah Clarke
“The technology in the field of stone management is exciting, and I think it offers patients a lot more options than what they've had in the past,” says Brian Stork, MD.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA clears stapler for use with da Vinci SP surgical system
April 10th 2025

FDA clears stapler for use with da Vinci SP surgical system

Hannah Clarke
This approval marks the first clearance of a stapler designed for single-port robotic surgery in the US.
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: @ Dr_Microbe - stock.adobe.com
April 10th 2025

Polygenic risk score may identify more clinically significant PCa than PSA, MRI

Hannah Clarke
"Building on decades of research into the genetic markers of prostate cancer, our study shows that the theory does work in practice – we can identify men at risk of aggressive cancers who need further tests and spare the men who are at lower risk from unnecessary treatments," says Professor Ros Eeles.
© 2025 MJH Life Sciences

All rights reserved.